McKesson Corporation (MCK) Debt to Assets Ratio: 0.10%
The debt to assets ratio for McKesson Corporation (MCK) is 0.10% as of Friday, June 19, 2026.
MCK Debt to Assets Ratio Metrics
DEBT TO ASSETS RATIO
0.10%
MCK Competitors' Debt to Assets Ratio
| NAME | MARKET CAP | DEBT TO ASSETS RATIO |
|---|---|---|
| McKesson Corporation (MCK) | $87.88B | 0.10% |
| Elevance Health Inc. (ELV)vs › | $84.37B | 0.27% |
| HCA Healthcare, Inc. (HCA)vs › | $83.23B | 0.83% |
| Medtronic plc (MDT)vs › | $101.86B | 0.30% |
| Cigna Corporation (CI)vs › | $73.88B | 0.20% |
| Boston Scientific Corporation (BSX)vs › | $67.35B | 0.28% |
| Bristol-Myers Squibb Company (BMY)vs › | $110.27B | 0.52% |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $62.84B | 0.07% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $114.63B | 0.15% |
| Stryker Corporation (SYK)vs › | $119.03B | 0.34% |
Leverage Ratios Comparison
Debt/Assets
0.1%
Debt/Equity
-3.97
Current Ratio
0.85
Interest Coverage
26.1x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
- Debt/Assets: Shows % of assets funded by creditors (bounded 0-100%)
- Debt/Equity: Shows debt relative to shareholder investment (can exceed 100%)
- Both measure leverage but from different perspectives
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
McKesson Corporation Debt to Assets Ratio Formula & Definition
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
McKesson Corporation Debt to Assets Ratio FAQ
- What is the debt to assets ratio for McKesson Corporation (MCK)?
- The debt to assets ratio for MCK stock is 0.10%.
About McKesson Corporation
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Brian S. Tyler